Auro-Dapagliflozin 10 mg

Dapagliflozin, the active ingredient in Auro-Dapagliflozin 10 mg, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor presented as a 10 mg tablet for oral use. It is used to manage blood sugar levels in adults with type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease.

GNH USA supplies Auro-Dapagliflozin 10 mg as a licensed, GDP-compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Auro-Dapagliflozin 10 mg is used to manage conditions related to glucose regulation and cardiovascular health. It is primarily indicated for the following conditions:

- Type 2 diabetes mellitus: Helps lower blood sugar levels in adults with type 2 diabetes when combined with diet and exercise. - Heart failure with reduced ejection fraction: Improves heart function and reduces the risk of hospitalization in patients with heart failure. - Chronic kidney disease: Helps manage and slow the progression of kidney disease in adults with type 2 diabetes.

Auro-Dapagliflozin 10 mg may cause various side effects, which can be categorized as common or serious.

Common Side Effects: - Increased urination: Helps remove excess glucose from the body. - Thirst: Due to increased urine output. - Dizziness: May occur as a result of changes in blood sugar levels. - Fatigue: Can be a result of the body's adjustment to lower blood sugar levels.

Serious or Rare Side Effects: - Urinary tract infections: Increased risk due to higher glucose levels in urine. - Hypoglycemia: Low blood sugar levels, especially when combined with other diabetes medications. - Dehydration: Due to increased urination, it is important to stay hydrated. - Kidney problems: May affect kidney function, particularly in patients with pre-existing kidney issues.

Auro-Dapagliflozin 10 mg should be used with caution and under the guidance of a healthcare provider. Important precautions include:

- Kidney function: Regular monitoring is essential, especially in patients with kidney issues. - Urinary tract infections: Increased risk due to higher glucose levels in urine; seek medical advice if symptoms occur. - Dehydration: Stay hydrated to prevent complications from increased urination. - Hypoglycemia: Monitor blood sugar levels, especially when combined with other diabetes medications. - Pregnancy: Consult a healthcare provider before use, as safety during pregnancy has not been established. - Store below 25°C: Keep in the original pack, protect from moisture.

Auro-Dapagliflozin 10 mg may interact with other medications, which can be categorized as major or moderate interactions.

Major Interactions (Avoid): - Insulin: Increased risk of hypoglycemia; close monitoring is required. - Other SGLT2 inhibitors: Avoid concurrent use to prevent additive effects. - Diuretics: May increase the risk of dehydration and electrolyte imbalances.

Moderate Interactions (Monitor Closely): - ACE inhibitors: May affect kidney function; regular monitoring is advised. - Beta-blockers: May mask symptoms of hypoglycemia; monitor blood sugar levels closely. - Nonsteroidal anti-inflammatory drugs (NSAIDs): May affect kidney function; use with caution.